News: Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine

Eli Lilly announced today that it will acquire Verve Therapeutics for up to $1.3 billion to develop single-dose base-editing treatments for people with high cardiovascular risk.

News: Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments Eli Lilly announced today that it will acquire Verve Therapeutics for up to $1.3 billion to develop single-dose base-editing treatments for people with high cardiovascular risk. By: Karen O'Hanlon Cohrt - Jun. 17, 2025 Eli Lilly and Verve Therapeutics announced today that Lilly will acquire Verve for up to $1.3 billion. Under the terms of the agreement, Lilly will commence a tender offer to acqui

related reading

• Significantly Enhancing Adult Intelligence With Gene Editing May Be Possible — LessWronglesswrong.com
• Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
• UK first to approve CRISPR treatment for diseases: what you need to knownature.com
• FDA Approves First CRISPR Gene Editing Treatment for Sickle Cell Disease | Scientific Americanscientificamerican.com
• CRISPR Gene Therapy: Applications, Limitations, and Implications for the Futurencbi.nlm.nih.gov
• Cure all diseasesworksinprogress.news
• Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
• Gene Genies: Inside The Revolutionary Biotech That Can Edit DNA Inside Living Humansforbes.com
• This baby boy was treated with the first personalized gene-editing drug | MIT Technology Reviewtechnologyreview.com
• Announcing Preventive — Preventivepreventive.bio
• Medicine's Endgamenotboring.co
• Curious cases of financial engineering in biotechowlposting.com